Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06BYR
|
||||
| Former ID |
DNC005841
|
||||
| Drug Name |
N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527800] | ||
| Formula |
C16H15NO4
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)CCC(=O)NO
|
||||
| InChI |
1S/C16H15NO4/c18-15(10-11-16(19)17-20)12-6-8-14(9-7-12)21-13-4-2-1-3-5-13/h1-9,20H,10-11H2,(H,17,19)
|
||||
| InChIKey |
NOELKUBXWDTLKR-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Interstitial collagenase | Target Info | Inhibitor | [527800] | |
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Bladder Cancer | |||||
| Activation of Matrix Metalloproteinases | |||||
| Degradation of collagen | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell surface interactions at the vascular wall | |||||
| Matrix Metalloproteinases | |||||
| References | |||||